INTRODUCTION {#s1}
============

In China in 2009, esophageal cancer (EC) was the fourth leading cause of cancer death and the fifth most common diagnosed malignancy \[[@R1]\]. Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of EC cases. Single nucleotide polymorphisms (SNPs), as individual genetic risk factors, might play a vital role in ESCC carcinogenesis in addition to certain environmental risk factors \[[@R2]\].

*S100A14* is located on chromosome 1q21 and is one of the least-characterized members of theS100 family \[[@R3]\]. S100A14 is a low molecular weight calcium-binding protein \[[@R3], [@R4]\]. Since loss of expression or overexpression of S100A14 has been reported in tumors, its functional role has been proposed to be organ-specific and involved in tumorigenesis \[[@R5]\]. S100A14 is also a target for p53 and could alter p53 transactivity and stability, and by regulating matrix metalloproteinase (MMP)2 transcription, S100A14 affects cell invasiveness in a p53-dependent manner \[[@R6]\].

S100 proteins take part in the process of terminal differentiation of the human epidermis \[[@R7]\] and have been implicated in cancer, as altered expression levels of some S100 proteins have been identified to correlate with tumor differentiation, including in ESCC. It has recently been reported that the S100 family member S100A14 plays a role in driving esophageal carcinogenesis, showing that extracellular S100A14 may affect EC cell proliferation and/or apoptosis via interaction with the receptor for advanced glycation end-products (RAGE) \[[@R8]\]. S100A14 can also regulate oral squamous cell carcinoma cell by modulating the expression of MMP1 and MMP9 \[[@R9]\]. One genetic variant of *S100A14* (461G\>A, rs11548103) is located in the 5′-untranslated region (UTR) and has been shown to disrupt a p53-binding site. This variant is correlated with decreased expression of *S100A14* both *in vitro* and *in vivo* in target tissues. Additionally, a previous study reported that rs11548103-A was associated with risk for ESCC \[[@R10]\].

*MutL homolog 1* (*MLH1*) is a member of the DNA mismatch repair (MMR) genes, which encode several highly conserved proteins. Deficiency in MMR may play important roles in the etiology of cancer. The rs1800734 (-93G/A) polymorphism in *MLH1* is located in the promoter region, which is responsible for the transcriptional activity of this gene.

SMAD7, an inhibitory SMAD, is a negative regulator of the transforming growth factor-beta (TGF-β) signaling pathway, which promotes the anti-inflammatory roles of TGF-β signaling via binding to the TGF-β-activated kinase (TAK)1-binding proteins that inhibit TAK1, TAB2 and TAB3 \[[@R11], [@R12]\]. The rs12953717-T allele at *SMAD7* has been associated with increased susceptibility to colorectal cancer (CRC) among both Caucasians and Asians \[[@R13]\].

Macrophage-derived chemokine (MDC), also known as C-C motif chemokine 22 (CCL22), is a chemokine secreted mainly by macrophages \[[@R14]\]. Rs4359426, a variant of *CCL22*, has been shown to associate with over-expression of *CCL22* mRNA and susceptibility to atopic dermatitis in a gain-of-function manner \[[@R15]\].

Genetic variants in *S100A14* (rs11548103G\>A)*, MLH1* (rs1800734 C\>T)*, SMAD7* (rs12953717C\>T) and *CCL22/MDC* (rs4359426C\>A) may contribute to the etiology of ESCC. In a hospital-based case-control study including 629 ESCC cases and 686 controls, we performed genotyping and tested the association of these four functional SNPs with ESCC in a Chinese population.

RESULTS {#s2}
=======

Characteristics of the study population {#s2_1}
---------------------------------------

Characteristics of the ESCC cases and controls are summarized in Table [1](#T1){ref-type="table"}. According to *χ*^2^ tests, the ESCC cases and controls were adequately matched for age and sex. Meanwhile, we found significant differences in smoking and drinking status between the ESCC cases and controls. Table [2](#T2){ref-type="table"} presents information on *S100A14* rs11548103G\>A, *MLH1* rs1800734 C\>T, *SMAD7* rs12953717 C\>T and *CCL22/MDC* rs4359426 C\>A. For these four genotyped SNPs, in our controls, the minor allele frequency (MAF) was very similar to the MAF for Chinese in database. Furthermore, in controls, goodness-of-fit *χ*^2^ tests indicated that the observed genotype frequencies were all in Hardy-Weinberg equilibrium (HWE) for these polymorphisms (Table [2](#T2){ref-type="table"}).

###### Distribution of selected demographic variables and risk factors in ESCC cases and controls

  Variable                Cases (*n* = 629)   Controls (*n* = 686)   *p*^a^           
  ----------------------- ------------------- ---------------------- -------- ------- ----------
  Age (years) mean ± SD   62.85 (± 8.13)      62.58 (± 7.89)                  0.541   
  Age (years)                                                                         0.155
  \< 63                   310                 49.28                  365      53.21   
  ≥ 63                    319                 50.72                  321      46.79   
  Sex                                                                                 0.185
  Male                    444                 70.59                  461      67.20   
  Female                  185                 29.41                  285      32.80   
  Tobacco use                                                                         \< 0.001
  Never                   355                 56.44                  499      72.74   
  Ever                    274                 43.56                  187      27.26   
  Alcohol use                                                                         \< 0.001
  Never                   428                 68.04                  526      76.68   
  Ever                    201                 31.96                  160      23.32   

^a^Two-sided *χ*^2^ test and student *t* test; Bold values are statistically significant (*p* \< 0.05).

###### Primary information for *S100A14* rs11548103 G\>A, *MLH1* rs1800734 C\>T, *SMAD7* rs12953717 C\>T and *CCL22/MDC* rs4359426 C\>A polymorphisms

  --------------------------------------------------------------------------------------------------------------------------------
  Genotyped SNPs                    S100A14 rs11548103 G\>A   MLH1rs1800734 C\>T   SMAD7rs12953717 C\>T   CCL22/MDCrs4359426C\>A
  --------------------------------- ------------------------- -------------------- ---------------------- ------------------------
  Chromosome                        Chr1                      Chr3                 Chr18                  Chr16

  Function                          UTR-5                     UTR-5                Intron                 missense

  Chr Pos\                          151854964                 37009950             44707927               55950234
  (Genome Build 36.3)                                                                                     

  Regulome DB Score^a^              5                         4                    5                      4

  TFBS^b^                           Y                         Y                    ---                    ---

  Splicing(ESE or ESS)              Y                         ---                  ---                    Y

  miRNA(miRanda)                    ---                       ---                  ---                    ---

  nsSNP                             ---                       ---                  ---                    Y

  MAF^c^ for Chinese in database    0.333                     0.415                0.183                  0.136

  MAF in our controls (*n* = 686)   0.323                     0.416                0.206                  0.149

  *p* value for HWE^d^\             0.741                     0.944                0.889                  0.520
  test in our controls                                                                                    

  Genotyping method^e^              LDR                       LDR                  LDR                    LDR

  \% Genotyping value               95.29%                    96.43%               95.13%                 98.63%
  --------------------------------------------------------------------------------------------------------------------------------

^a^ <http://www.regulomedb.org/>.

^b^ TFBS:transcription factor binding site (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>).

^c^ MAF: minor allele frequency, *S100A14* rs11548103 G\>A MAF is in CHB+JPT population.

^d^ HWE: Hardy--Weinberg equilibrium.

^e^ LDR: ligation detection reaction.

Association between rs11548103, rs1800734, rs12953717 and rs4359426 and risk of ESCC {#s2_2}
------------------------------------------------------------------------------------

As shown in Table [3](#T3){ref-type="table"}, the GG, GA and AA allele frequencies of rs11548103 were 51.2, 37.8 and 10.9%, respectively, in the ESCC group and 45.5, 44.3 and 10.2%, respectively, in the healthy control group. When the GG genotype was adopted as the reference group, the GA genotype significantly decreased the risk of ESCC (GA vs. GG: adjusted OR = 0.73, 95% CI = 0.57--0.93, *p* = 0.009). In the dominant model, we also found that carriers of the GA/AA variants had a decreased risk of ESCC compared with carriers of the GG genotype (GA/AA vs. GG: adjusted OR = 0.76, 95% CI = 0.61--0.95, *p* = 0.018) (Table [3](#T3){ref-type="table"}).

###### Logistic regression analyses of associations between *S100A14* rs11548103 G\>A, *MLH1* rs1800734 C\>T, *SMAD7* rs12953717 C\>T and *CCL22/MDC* rs4359426 C\>A polymorphisms and risk of ESCC

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Genotype                    Cases\        Controls\     Crude OR\   *p*    Adjusted OR^a^\         *p*                                 
                              (*n* = 629)   (*n* = 686)   (95% CI)           (95% CI)                                                    
  --------------------------- ------------- ------------- ----------- ------ ----------------------- ----------- ----------------------- -----------
  *S100A14* rs11548103 G\>A                                                                                                              

  GG                          309           51.2          296         45.5   1.00                                1.00                    

  GA                          228           37.8          288         44.3   **0.76 (0.60--0.96)**   **0.022**   **0.73 (0.57--0.93)**   **0.009**

  AA                          66            10.9          66          10.2   0.96 (0.66--1.40)       0.823       0.90 (0.61--1.33)       0.597

  AA vs.GA vs.GG                                                                                                                         0.064

  GA + AA                     294           48.8          354         54.5   **0.80 (0.64--0.99)**   **0.044**   **0.76 (0.61--0.95)**   **0.018**

  GG + GA                     537           89.1          584         89.8   1.00                                1.00                    

  AA                          66            10.9          66          10.2   1.09 (0.76--1.56)       0.648       1.04 (0.72--1.51)       0.819

  G allele                    846           70.1          880         67.7   1.00                                                        

  A allele                    360           29.9          420         32.3   0.89 (0.75--1.06)       0.185                               

  *MLH1*\                                                                                                                                
  rs1800734A\>G                                                                                                                          

  AA                          207           33.9          224         34.1   1.00                                1.00                    

  AG                          291           47.6          320         48.7   0.98 (0.77--1.26)       0.899       0.92 (0.72--1.18)       0.518

  GG                          113           18.5          113         17.2   1.08 (0.78--1.49)       0.631       1.03 (0.74--1.43)       0.849

  GG vs.AG vs.AA                                                                                                                         0.827

  AG + GG                     404           66.1          433         65.9   1.01 (0.80--1.27)       0.936       0.95 (0.75--1.20)       0.668

  AA + AG                     498           81.5          544         82.8   1.00                                1.00                    

  GG                          113           18.5          113         17.2   1.09 (0.82--1.46)       0.547       1.08 (0.81--1.45)       0.589

  A allele                    705           57.7          768         58.4   1.00                                                        

  G allele                    517           42.3          546         41.6   1.03 (0.88--1.21)       0.700                               

  *SMAD7* rs12953717 C\>T                                                                                                                

  CC                          355           59.2          410         63.0   1.00                                1.00                    

  CT                          212           35.3          214         32.9   1.14 (0.90--1.45)       0.266       1.19 (0.93--1.51)       0.162

  TT                          33            5.5           27          4.1    1.41 (0.83--2.39)       0.201       1.37 (0.80--2.34)       0.255

  TT vs.CT vs.CC                                                                                                                         0.288

  CT + TT                     245           40.8          241         37.0   1.17 (0.94--1.47)       0.167       1.21 (0.96--1.53)       0.109

  CC + CT                     567           94.5          624         95.9   1.00                                1.00                    

  TT                          33            5.5           27          4.1    1.35 (0.80--2.27)       0.265       1.29 (0.76--2.19)       0.353

  C allele                    922           76.8          1034        79.4   1.00                                                        

  T allele                    278           23.2          268         20.6   1.16 (0.96--1.41)       0.118                               

  *CCL22/MDC*rs4359426C\>A                                                                                                               

  CC                          461           74.8          491         72.1   1.00                                1.00                    

  CA                          138           22.4          177         26.0   0.83 (0.64--1.07)       0.155       0.86 (0.66--1.12)       0.254

  AA                          17            2.8           13          1.9    1.39 (0.67--2.90)       0.376       1.38 (0.65--2.91)       0.398

  AA vs.CA vs.CC                                                                                                                         0.217

  CA + AA                     155           25.2          190         27.9   0.87 (0.68--1.11)       0.265       0.90 (0.70--1.15)       0.391

  CC + CA                     599           97.2          668         98.1   1.00                                1.00                    

  AA                          17            2.8           13          1.9    1.46 (0.70--3.03)       0.312       1.43 (0.68--3.01)       0.343

  C allele                    1060          86.0          1159        85.1   1.00                                                        

  A allele                    172           14.0          203         14.9   0.93 (0.74--1.15)       0.496                               
  --------------------------------------------------------------------------------------------------------------------------------------------------

^a^Adjusted for age, sex, smoking and drinking status; Bold values are statistically significant (*p* \< 0.05).

Logistic regression analyses indicated that rs1800734, rs12953717 and rs4359426 were not associated with the risk of ESCC in any of the models (Table [3](#T3){ref-type="table"}).

Stratification analyses on rs11548103 {#s2_3}
-------------------------------------

To evaluate the effects of rs11548103 on ESCC risk according to different age groups, sex, tobacco consumption and drinking status, we performed stratification analyses. A significantly decreased risk of ESCC associated with rs11548103 was evident among younger patients (GA vs. GG: adjusted OR = 0.69, 95% CI = 0.49--0.98, *p* = 0.038), male patients (GA/AA vs. GG: adjusted OR = 0.70, 95% CI = 0.53--0.92, *p* = 0.012) and patients who never drink (GA/AA vs. GG: adjusted OR = 0.72, 95% CI = 0.55--0.94, *p* = 0.017) or smoke (GA/AA vs. GG: adjusted OR = 0.72, 95% CI = 0.54--0.96, *p* = 0.025) (Table [4](#T4){ref-type="table"}).

###### Stratified analyses between *S100A14* rs11548103 G\>A polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable             S100A14 rs11548103 G\>A(case/control) a   Adjusted OR b (95%CI); p; phc                                                                                                                     
  -------------------- ----------------------------------------- ------------------------------- ------- --------- ------ ------------------------------ -------------------------- ------------------------------ --------------------------
  Sex                                                                                                                                                                                                              

   Male                221/194                                   159/200                         47/42   206/242   1.00   **0.66 (0.49--0.88);**\        0.90 (0.56--1.44);\        **0.70 (0.53--0.92);**\        1.09 (0.70--1.72);\
                                                                                                                          ***p*: 0.005**; *p*~h~:0.311   *p*: 0.659; *p*~h~:0.869   ***p*: 0.012**;*p*~h~:0.420    *p*: 0.699; *p*~h~:0.628

   Female              88/102                                    69/88                           19/24   88/112    1.00   0.88 (0.57--1.35);\            0.92 (0.47--1.81);\        0.89 (0.59--1.33);\            0.97 (0.51--1.86);\
                                                                                                                          *p*: 0.559;*p*~h~: 0.311       *p*: 0.808;*p*~h~:0.869    *p*: 0.565;*p*~h~:0.420        *p*: 0.937;*p*~h~:0.628

  Age                                                                                                                                                                                                              

   \< 63               154/155                                   110/149                         34/40   144/189   1.00   **0.69 (0.49--0.98);**\        0.85 (0.50--1.43);\        0.73 (0.53--1.00);\            1.00 (0.60--1.65);\
                                                                                                                          ***p*: 0.038;** *p*~h~:0.873   *p*: 0.532; *p*~h~:0.488   *p*: 0.051; *p*~h~:0.739       *p*: 0.989; *p*~h~:0.494

   ≥ 63                155/141                                   118/139                         32/26   150/165   1.00   0.76 (0.54--1.06);\            0.97 (0.55--1.74);\        0.79 (0.57--1.09);\            1.11 (0.64--1.94);\
                                                                                                                          *p*: 0.104;*p*~h~:0.873        *p*: 0.929;*p*~h~:0.488    *p*: 0.152;*p*~h~:0.739        *p*: 0.708;*p*~h~:0.494

  Smoking status                                                                                                                                                                                                   

   Never               186/219                                   119/206                         34/46   153/252   1.00   **0.68 (0.50--0.92);**\        0.92 (0.56--1.50);\        **0.72 (0.54--0.96);**\        1.09 (0.68--1.75);\
                                                                                                                          ***p*: 0.012;** *p*~h~:0.431   *p*: 0.732; *p*~h~:0.728   ***p*: 0.025**; *p*~h~:0.429   *p*: 0.730; *p*~h~:0.871

   Ever                123/77                                    109/82                          32/20   141/102   1.00   0.84 (0.56--1.27);\            0.97 (0.51--1.85);\        0.87 (0.59--1.28);\            1.06 (0.58--1.95);\
                                                                                                                          *p*: 0.412;*p*~h~:0.431        *p*: 0.932;*p*~h~:0.728    *p*: 0.475;*p*~h~:0.429        *p*: 0.853;*p*~h~:0.871

  Alcoholconsumption                                                                                                                                                                                               

   Never               217/229                                   145/220                         47/48   192/268   1.00   **0.66 (0.50--0.89);**\        0.97 (0.61--1.55);\        **0.72 (0.55--0.94);**\        1.17 (0.75--1.82);\
                                                                                                                          ***p*: 0.006;** *p*~h~:0.364   *p*: 0.907; *p*~h~:0.492   ***p*: 0.017;** *p*~h~:0.602   *p*: 0.498; *p*~h~:0.330

   Ever                92/67                                     83/68                           19/18   102/86    1.00   0.93 (0.59--1.47);\            0.80 (0.38--1.67);\        0.90 (0.58--1.39);\            0.83 (0.41--1.67);\
                                                                                                                          *p*: 0.747;*p*~h~:0.364        *p*: 0.551;*p*~h~:0.492    *p*: 0.638;*p*~h~:0.602        *p*: 0.601;*p*~h~:0.330
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ The genotyping was successful in 603 (95.9%) ESCC cases, and 650 (94.8%) controls for *S100A14* rs11548103 G\>A.

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

^c^ *p*~h~ for heterogeneity.

DISCUSSION {#s3}
==========

In the present hospital-based case-control study of ESCC, we identified that rs11548103 was associated with decreased risk of ESCC.

Accumulating evidence has demonstrated the importance of the S100 family in cell migration, invasion and cancer metastasis \[[@R6]\]. S100A14, a member of the S100 family, is involved in several vital functional and pathological processes \[[@R16]\]. Additionally, it is predicted to be under tight transcriptional and post-translational regulation \[[@R16]\]. A previous phylogenetic investigation of the S100 family indicated that S100A14 is different from the other members of the S100 family (except S100A13) due to alterations in several key amino acid residues, which are responsible for the binding of calcium, suggesting that the activity of the S100A14 protein is independent of calcium \[[@R5]\]. In addition, functional studies have reported that S100A14 induces cell cycle arrest or apoptosis in ESCC \[[@R8], [@R10]\] and regulates the cell cycle in a p53- or RAGE-dependent manner.

Chen et al. reported that high levels of S100A14 associated significantly with elevated levels of MMP2 in clinical breast cancer samples with wild-type p53, but not in those with mutant p53 \[[@R5]\]. Although the function of S100A14 in breast cancer remains to be elucidated, it has been suggested that S100A14 binds HER2 and modulates its phosphorylation, leading to HER2-stimulated cell proliferation, indicating that S100A14 may be a functional partner of HER2 in HER2-positive breast tumors \[[@R5]\]. Decreased expression of S100A14 with its genetic variant may be associated with an undifferentiated phenotype and poor prognosis in gastric cancer \[[@R17]\]. In a previous study, rs11548103was demonstrated to diminish a p53-binding site and was correlated with decreased expression of *S100A14* both *in vitro* and *in vivo* in target tissues \[[@R10]\]. Furthermore, a case-control analysis showed that the *S100A14* rs11548103-A allele was associated with susceptibility to ESCC among smokers \[[@R10]\]. However, in our research, we found a protective effect of rs11548103. Additionally, rs11548103 appears to be a functional locus according to a SNP functional prediction website (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>). However, the etiology of rs11548103 is not clearly known and requires further investigation.

Using the Power and Sample Size Calculation program (PS, version 3.0, 2009, <http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>), with α = 0.05, the power of our analysis was 0.597 to detect an effect with an adjusted OR of 0.76 in 603 ESCC cases and 650 non-cancer controls.

In this case-control study, there were several limitations. First, the ESCC patients and non-cancer controls were enrolled from local hospitals, where inherent bias may have occurred. Second, the polymorphisms we studied do not provide an extensive view of the genetic variability present. In the future, fine-mapping studies are required. Third, because of the limited sample size and absence of a validation cohort, the statistical power of our study was limited. Fourth, we did not obtain detailed cancer metastasis and survival information, which further restricted the analysis of *S100A14* rs11548103 G\>A polymorphism in ESCC progression and prognosis. The actual power might have decreased considerably upon stratification because of the very small sample numbers. Finally, *in vitro* or tissue-specific biological characterizations are required to confirm the current preliminary findings.

In conclusion, our study found that rs11548103 may decrease the risk of ESCC. Tissue-specific biological characterization and a replication study with larger populations are required to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Ethical approval of the study protocol {#s4_1}
--------------------------------------

We complied with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects and/or animals. The review board of Jiangsu University (Zhenjiang, China) approved the present case-control study. Written informed consent was provided by all participants.

ESCC patients and controls {#s4_2}
--------------------------

From two affiliated hospitals (the Affiliated People's Hospital and the Affiliated Hospital of Zhenjiang, China), between October 2008 and December 2010, 629 cases with ESCC were recruited consecutively. All cases of ESCC were diagnosed by pathological analyses. Patients who previously had a history of malignancy or any metastasized cancer treated with radiotherapy or chemotherapy were excluded. For the control group, 686 non-cancer patients were matched to the ESCC cases with regard to age (± 5 years) and sex. The controls were recruited during the same time period from the two affiliated hospitals of Jiangsu University. Most of the non-cancer controls were being treated for trauma.

Using a pre-tested questionnaire, two trained interviewers questioned each participant personally. The demographic data information (e.g., age, sex) and ESCC-related risk factors (such as smoking and alcohol consumption) were obtained.

Isolation of DNA and genotyping by ligation detection reaction (LDR) {#s4_3}
--------------------------------------------------------------------

According to the manufacturer's protocol, genomic DNA was isolated from whole blood \[[@R18]\]. With technical support from the Biotechnology Company (Biowing Biotechnologies Inc., Shanghai, China), the DNA samples were genotyped using the PCR-LDR method \[[@R19]\]. One hundred sixty (12.17%) were randomly selected for quality control checks and the reproducibility was 100%.

Statistical analyses {#s4_4}
--------------------

Using *χ*^2^ statistical tests, we tested whether there were differences between cases and controls in the distributions of demographic characteristics (age and sex), selected variables (smoking and alcohol consumption), and the rs11548103, rs1800734, rs12953717 and rs4359426 genotypes. Using logistic regression analyses, the relationship of these four SNPs with risk of ESCC was assessed in terms of crude ORs and ORs adjusted for age, sex and smoking and alcohol consumption. HWE was tested by a goodness-of-fit *χ*^2^ test among the control subjects. All statistical analyses were performed with SAS 9.1.3 (SAS Institute, Cary, NC, USA).
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